| US 7,473,561 B2 | ||
| Bone morphogenetic protein-2 in the treatment and diagnosis of cancer | ||
| John Langenfeld, Flemington, N.J. (US) | ||
| Assigned to University of Medicine and Dentistry of New Jersey, Somerset, N.J. (US) | ||
| Filed on May 17, 2006, as Appl. No. 11/435,852. | ||
| Application 11/435852 is a division of application No. 10/692824, filed on Oct. 23, 2003, abandoned. | ||
| Application 10/692824 is a continuation in part of application No. 10/044716, filed on Jan. 11, 2002, abandoned. | ||
| Claims priority of provisional application 60/261252, filed on Jan. 12, 2001. | ||
| Prior Publication US 2006/0198844 A1, Sep. 07, 2006 | ||
| Int. Cl. G01N 33/566 (2006.01) | ||
| U.S. Cl. 436—501 [530/350; 435/4] | 1 Claim |
| 1. A method for identifying a candidate agent for use in reducing vascularization in non-small cell lung tumors comprising:
(a) contacting bone morphogenetic protein-2 (BMP-2) and BMP-2 receptor IB in the presence of a test agent under conditions
suitable to permit the formation of a BMP-2/BMP-2 receptor complex, wherein said BMP-2 comprises the amino acid sequence of
amino acids 283-396 of SEQ ID NO: 2 and wherein said BMP-2 receptor IB comprises the amino acid sequence of amino acids 14-502
of SEQ ID NO: 14;
(b) determining the amount of the BMP-2/BMP-2 receptor complex formed in the presence of said test agent; and
(c) determining that said test agent is a candidate agent for use in reducing vascularization in non-small cell lung tumors
if the amount of the BMP-2/BMP-2 receptor complex formed in the presence of said test agent is lower than the amount of the
BMP-2/BMP-2 receptor complex formed in the absence of said test agent,
thereby identifying a candidate agent for use in reducing vascularization in non-small cell lung tumors.
|